期刊
JOURNAL OF BIOMEDICAL SCIENCE
卷 30, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12929-023-00982-8
关键词
Chimeric antigen receptor (CAR)-T cell therapies; Cytokine release syndrome; Immune effector cell-associated neurotoxicity syndrome; Macrophage activation syndrome
This article provides a summary of the adverse effects of CAR-T cell therapies, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and CAR T-cell associated HLH. It discusses the pathophysiology, symptoms, grading, and diagnosis systems, as well as management strategies. The article also gives an overview of measures and modifications currently being explored to limit toxicity in CAR-T cells.
Chimeric antigen receptor (CAR)-T cell therapies have been approved by FDA to treat relapsed or refractory hematological malignancies. However, the adverse effects of CAR-T cell therapies are complex and can be challenging to diagnose and treat. In this review, we summarize the major adverse events, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and CAR T-cell associated HLH (carHLH), and discuss their pathophysiology, symptoms, grading, and diagnosis systems, as well as management. In a future outlook, we also provide an overview of measures and modifications to CAR-T cells that are currently being explored to limit toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据